References
- Macrin D, Joseph JP, Pillai AA, et al. Eminent sources of adult mesenchymal stem cells and their therapeutic imminence. Stem Cell Rev. 2017;13:741–756.
- Kastrup J, Mygind ND, Qayyum AA, et al. Mesenchymal stromal cell therapy in ischemic heart disease. Scand Cardiovasc J. 2016;50:293–299.
- Huang S-J, Fu R-H, Shyu W-C, et al. Adipose-derived stem cells: isolation, characterization, and differentiation potential. Cell Transplant. 2013;22:701–709.
- Martin I, De Boer J, Sensebe L. MSC Committee of the International Society for Cellular Therapy. A relativity concept in mesenchymal stromal cell manufacturing. Cytotherapy. 2016;18:613–620.
- Haack-Sørensen M, Follin B, Juhl M, et al. Culture expansion of adipose derived stromal cells. A closed automated Quantum Cell Expansion System compared with manual flask-based culture. J Transl Med. 2016;14:319.
- Juhl M, Tratwal J, Follin B, et al. Comparison of clinical grade human platelet lysates for cultivation of mesenchymal stromal cells from bone marrow and adipose tissue. Scand J Clin Lab Invest. 2016;76:93–104.
- Riis S, Nielsen FM, Pennisi CP, et al. Comparative analysis of media and supplements on initiation and expansion of adipose-derived stem cells. Stem cells. Transl Med. 2016;5:314–324.
- Halme DG, Kessler DA. FDA regulation of stem-cell-based therapies. N Engl J Med. 2006;355:1730–1735.
- van der Valk J, Brunner D, De Smet K, et al. Optimization of chemically defined cell culture media–replacing fetal bovine serum in mammalian in vitro methods. Toxicol in Vitro. 2010;24:1053–1063.
- Pérez-Ilzarbe M, Díez-Campelo M, Aranda P, et al. Comparison of ex vivo expansion culture conditions of mesenchymal stem cells for human cell therapy. Transfusion. 2009;49:1901–1910.
- Bieback K. Platelet lysate as replacement for fetal bovine serum in mesenchymal stromal cell cultures. Transfus Med Hemother. 2013;40:326–335.
- Fekete N, Rojewski MT, Lotfi R, et al. Essential components for ex vivo proliferation of mesenchymal stromal cells. Tissue Eng Part C Methods. 2014;20:129–139.
- Follin B, Tratwal J, Haack-Sørensen M, et al. Identical effects of VEGF and serum-deprivation on phenotype and function of adipose-derived stromal cells from healthy donors and patients with ischemic heart disease. J Transl Med. 2013;11:219.
- Lambrechts T, Papantoniou I, Rice B, et al. Large-scale progenitor cell expansion for multiple donors in a monitored hollow fibre bioreactor. Cytotherapy. 2016;18:1219–1233.
- Follin B, Juhl M, Cohen S, et al. Human adipose-derived stromal cells in a clinically applicable injectable alginate hydrogel: phenotypic and immunomodulatory evaluation. Cytotherapy. 2015;17:1104–1118.
- Bourin P, Bunnell BA, Casteilla L, et al. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International So. Cytotherapy. 2013;15:641–648.
- Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–317.
- Rojewski MT, Fekete N, Baila S, et al. GMP-compliant isolation and expansion of bone marrow-derived MSCs in the closed, automated device quantum cell expansion system. Cell Transplant. 2013;22:1981–2000.
- Nold P, Brendel C, Neubauer A, et al. Good manufacturing practice-compliant animal-free expansion of human bone marrow derived mesenchymal stroma cells in a closed hollow-fiber-based bioreactor. Biochem Biophys Res Commun. 2013;430:325–330.
- Hanley PJ, Mei Z, Durett AG, et al. Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System. Cytotherapy. 2014;16:1048–1058.
- Lechanteur C. Large-scale clinical expansion of mesenchymal stem cells in the gmp-compliant, closed automated quantum® cell expansion system: comparison with expansion in traditional T-flasks. J Stem Cell Res Ther. 2014;4:1–11.
- Qayyum AA, Haack-Sørensen M, Mathiasen AB, et al. Adipose-derived mesenchymal stromal cells for chronic myocardial ischemia (MyStromalCell Trial): study design. Regen Med. 2012;7:421–428.
- Haack-Sørensen M, Friis T, Mathiasen AB, et al. Direct intramyocardial mesenchymal stromal cell injections in patients with severe refractory angina: one-year follow-up. Cell Transplant. 2013;22:521–528.
- Mathiasen AB, Qayyum AA, Jørgensen E, et al. Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial). Eur Heart J. 2015;36:1744–1753.
- Schallmoser K, Rohde E, Reinisch A, et al. Rapid large-scale expansion of functional mesenchymal stem cells from unmanipulated bone marrow without animal serum. Tissue Eng Part C Methods. 2008;14:185–196.
- Naaijkens BA, Niessen HWM, Prins H-J, et al. Human platelet lysate as a fetal bovine serum substitute improves human adipose-derived stromal cell culture for future cardiac repair applications. Cell Tissue Res. 2012;348:119–130.
- Trojahn Kølle S-F, Oliveri RS, Glovinski PV, et al. Pooled human platelet lysate versus fetal bovine serum—investigating the proliferation rate, chromosome stability and angiogenic potential of human adipose tissue-derived stem cells intended for clinical use. Cytotherapy. 2013;15:1086–1097.
- Castiglia S, Mareschi K, Labanca L, et al. Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions. Cytotherapy. 2014;16:750–763.
- Burnouf T, Strunk D, Koh MBC, et al. Human platelet lysate: replacing fetal bovine serum as a gold standard for human cell propagation? Biomaterials. 2016;76:371–387.